Source: International Congress 2014 – ERS/Lancet and Lancet Respiratory Medicine joint session: complicating infections in respiratory disease and critical care
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J.S. Elborn (Belfast, United Kingdom). Managing antimicrobial resistance in cystic fibrosis. International Congress 2014 – ERS/Lancet and Lancet Respiratory Medicine joint session: complicating infections in respiratory disease and critical care

Member's Comments

No comment yet.

Related content which might interest you: Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006 Antibiotic treatment of cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 188-202 Year: 2014 Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005 The role of antimicrobial peptides in cystic fibrosis in childhood. Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens Source: Eur Respir Rev, 28 (152) 190041; 10.1183/16000617.0041-2019 Year: 2019 Azithromycin in cystic fibrosis Source: Eur Respir J 2005; 25: 771 Year: 2005 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Susceptibility of problem respiratory pathogens to levofloxacin in cystic fibrosis (CF) Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002 Fosfomycin for pseudomonas related exacerbations of cystic fibrosis Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002 The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Azoles therapeutic drug monitoring and fungal antimicrobial resistance in adults with Cystic Fibrosis Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016 Year: 2017 Emerging pathogens in cystic fibrosis Source: International Congress 2019 – State of the art session: Paediatric respiratory diseases Year: 2019 Antimicrobial peptides in the real world: implications for cystic fibrosis Source: Eur Respir J 2007; 29: 617-618 Year: 2007 Symptomatic sinus disease and use of antibiotics in cystic fibrosis Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010 Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020